Zobrazeno 1 - 10
of 336
pro vyhledávání: '"Federal spending"'
Autor:
Scorsone, Eric
Publikováno v:
Research in the History of Economic Thought and Methodology: Including a Symposium on John Kenneth Galbraith: Economic Structures and Policies for the Twenty-first Century
Autor:
Xueguang Zhou1
Publikováno v:
Administrative Science Quarterly. Dec95, Vol. 40 Issue 4, p704-706. 3p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Crain, W. Mark
Publikováno v:
Public Choice. Jun95, Vol. 83 Issue 3/4, p375-377. 3p.
Publikováno v:
International Journal of Research in Marketing. 38:120-135
The current research extends past work on how consumers (as “observers”) view ethical choices made by others (“actors”). Using a person-centered approach to moral judgments, we show that consumers are judged differentially, based on their inc
Autor:
Ernest M. Zampelli, Steven T. Yen
Publikováno v:
Review of Policy Research. 38:6-30
Autor:
Lucas González, Tracy Beck Fenwick
Publikováno v:
Publius: The Journal of Federalism. 51:283-306
Throughout Latin American federations, programmatic welfare spending is increasingly nationally oriented and bureaucratically delivered. By explaining the logic and the effects of combining two types of federal spending, discretionary and non-discret
Publikováno v:
Party Politics. 28:38-47
We investigate the motivations driving members of the US Congress to introduce bills that require new federal spending, testing a classic “party matters” hypothesis that spending is motivated by partisanship with Democrats spending more on social
Publikováno v:
Journal of Dermatological Treatment. 33:575-579
Immunomodulators are the most expensive prescription medications used in dermatology for chronic skin conditions. Each year, rising costs for immunomodulators pose significant financial burdens on patients and the healthcare system as a whole. Using